Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

terminated133%
unknown267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_1

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

NCT04310592
unknownphase_1

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

NCT04309084
unknownphase_1

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

NCT04365101

Clinical Trials (3)

Showing 3 of 3 trials
NCT04310592Phase 1

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Terminated
NCT04309084Phase 1

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Unknown
NCT04365101Phase 1

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Unknown

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3